PLYMOUTH MEETING, Pa., June 25, 2024 /PRNewswire/ -- Braeburn Inc. announces the publication of a post hoc analysis in the Journal of the American Medical Association (JAMA) Network Open. The analysis evaluated data in patients with evidence of fentanyl use from the Phase 3 Clinical Efficacy and Safety trial comparing BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII) to daily sublingual buprenorphine/naloxone (SL BPN/NX) in patients with moderate to severe opioid use disorder (OUD)..

宾夕法尼亚州普利茅斯会议（PLYMOUTH MEETING，Pa），2024年6月25日/PRNewswire/--Braeburn Inc.宣布在《美国医学会杂志》（JAMA）网络公开版上发表一项事后分析。该分析评估了3期临床疗效和安全性试验中芬太尼使用证据的患者的数据，该试验比较了BRIXADI（丁丙诺啡）皮下缓释注射液（CIII）与每日舌下丁丙诺啡/纳洛酮（SL BPN/NX）在中度至重度阿片类药物使用障碍（OUD）患者中的应用。。

'Fentanyl is a primary driver of the continued growth of the opioid epidemic. The findings support prior observational studies that buprenorphine is effective against fentanyl, and is consistent with evidence from the BRIXADI Phase 3 Study,' said Edward V. Nunes, M.D., Professor of Psychiatry, Columbia University Irving Medical Center Department of Psychiatry.

芬太尼是阿片类药物疫情持续增长的主要驱动因素。哥伦比亚大学欧文医学中心精神病学系精神病学教授爱德华·努内斯（EdwardV.Nunes）医学博士说，这些发现支持了先前的观察性研究，即丁丙诺啡对芬太尼有效，并且与BRIXADI 3期研究的证据一致。

'Further research is needed to assess the efficacy of medications for OUD in the current landscape.'.

“需要进一步的研究来评估药物在当前情况下对OUD的疗效。”。

The Phase 3, 24-week, randomized, double-blind, double-dummy active-controlled, multicenter, study was conducted at 35 US outpatient clinical centers. The post hoc analysis included a subgroup of 123 participants (BRIXADI, n=64; SL BPN/NX, n=59) who had evidence of baseline fentanyl use. The Phase 3 trial was designed to include participants characteristic of the patient population with moderate to severe OUD. .

这项3期、24周、随机、双盲、双模拟、主动控制、多中心的研究在美国35个门诊临床中心进行。事后分析包括123名参与者（BRIXADI，n=64；SL BPN/NX，n=59）的亚组，他们有基线芬太尼使用的证据。第三阶段试验旨在包括具有中度至重度OUD患者人群特征的参与者。。

Key highlights of the Post Hoc Analysis:

事后分析的关键要点：

Assessments in this analysis included urine toxicology for illicit opioid use including fentanyl, Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), Visual Analog Scale (VAS), and adverse events (AEs).

该分析中的评估包括非法使用阿片类药物的尿液毒理学，包括芬太尼，临床阿片类药物戒断量表（COWS），主观阿片类药物戒断量表（SOWS），视觉模拟量表（VAS）和不良事件（AE）。

In the fentanyl-positive subgroup, the mean percentage of urine samples negative for fentanyl during the study was 74.6% for the BRIXADI arm versus 61.9% for SL BPN/NX.

。

In the fentanyl-positive subgroup, the mean percentage of urine samples negative for opioids was 28.5% for the BRIXADI arm versus 18.8% for SL BPN/NX. Similarly, in the fentanyl-negative subgroup, the mean percentage of urine samples negative for opioids was 36.7% for BRIXADI versus 30.6% in the SL BPN/NX arm. .

在芬太尼阳性亚组中，BRIXADI组阿片类药物阴性尿液样本的平均百分比为28.5%，而SL BPN/NX为18.8%。同样，在芬太尼阴性亚组中，BRIXADI的阿片类药物阴性尿液样本的平均百分比为36.7%，而SL BPN/NX组为30.6%。。

No substantial variance was observed in rates of study completion between fentanyl-positive and fentanyl-negative subgroups (60.2% and 56.7%, respectively).

芬太尼阳性和芬太尼阴性亚组之间的研究完成率没有显着差异（分别为60.2%和56.7%）。

With the exception of injection-site AEs such as swelling, inflammation, and induration, the observed AEs from this analysis were consistent with the known safety profile of BPN. Three nonfatal heroin overdoses were reported overall: one in the fentanyl-negative subgroup and two in the fentanyl-positive subgroup, all occurred in patients receiving SL BPN/NX. .

除了注射部位的AE（例如肿胀，炎症和硬结）外，从该分析中观察到的AE与已知的BPN安全性特征一致。总体上报告了三种非致命性海洛因过量：芬太尼阴性亚组中的一种和芬太尼阳性亚组中的两种，均发生在接受SL BPN/NX的患者中。。

Limitations of the post hoc analysis include that patients were primarily using heroin mixed with fentanyl. The analysis was not prespecified and the parent trial was not designed to assess the differences in treatment response between the subgroups. Differences in outcomes could be related to overall disease severity rather than fentanyl use..

事后分析的局限性包括患者主要使用与芬太尼混合的海洛因。分析没有预先指定，父母试验的目的不是评估亚组之间治疗反应的差异。结果的差异可能与整体疾病的严重程度有关，而不是芬太尼的使用。。

'This is the first study that evaluated data from patients testing positive for fentanyl at baseline in a phase 3 trial comparing the safety and effectiveness of long-acting buprenorphine to SL BPN/NX for the treatment of OUD,' remarked Natalie R. Budilovsky-Kelley, PharmD, Senior Director, Medical Affairs at Braeburn.

Braeburn医学部高级主任Natalie R.Budilovsky Kelley表示：“这是第一项评估芬太尼基线检测阳性患者数据的研究，该研究比较了长效丁丙诺啡与SL BPN/NX治疗OUD的安全性和有效性。”。

'These findings provide additional information regarding treatment of patients with OUD who are using fentanyl.'1 .

“这些发现提供了有关使用芬太尼治疗OUD患者的额外信息。”一。

The full publication 'Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder with Fentanyl Use' is available online at JAMA Network Open today.

完整的出版物“缓释注射液与舌下丁丙诺啡治疗芬太尼使用阿片类药物使用障碍”可在今天开放的JAMA网络在线获得。

'We are grateful to partner with researchers that share our unwavering commitment to those impacted by OUD to address this urgent public health crisis,' remarked Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer at Braeburn. 'Braeburn remains committed to furthering the scientific understanding of the treatment of OUD.'.

布劳伯恩首席医疗官约书亚·M·科恩（JoshuaM.Cohen）医学博士、公共卫生硕士（MPH）和法尔斯（FAHS）表示：“我们感谢与研究人员合作，他们对那些受乌德影响的人做出了坚定不移的承诺，以应对这场紧迫的公共卫生危机。”Braeburn仍然致力于促进对乌德治疗的科学理解。”。

About the Phase 3 TrialThe data were collected during a 24-week, randomized, double-blind trial (NCT02651584) conducted from December 2015 to November 2016 across 35 outpatient sites in the United States. Patients were randomized to daily SL placebo alongside BRIXADI weekly (first 12 weeks; Phase 1) and BRIXADI monthly (last 12 weeks; Phase 2); or to daily SL BPN/NX (24 weeks) with matched weekly and monthly subcutaneous placebo injections (SL-BPN/NX group).

关于第三阶段试验，数据收集于2015年12月至2016年11月在美国35个门诊点进行的为期24周的随机双盲试验（NCT02651584）。；或每日SL-BPN/NX（24周），每周和每月皮下注射安慰剂（SL-BPN/NX组）。

Of the 428 patients included in the study, more than 28% had evidence of fentanyl use at baseline..

在该研究纳入的428名患者中，超过28%的患者在基线时有芬太尼使用的证据。。

About BRIXADI®INDICATIONS AND USAGEBRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

关于BRIXADI®适应症和用途BRIXADI用于治疗已经开始使用单剂量透粘膜丁丙诺啡产品治疗或已经接受丁丙诺啡治疗的患者的中度至重度阿片类药物使用障碍。

BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.

BRIXADI应作为包括咨询和心理社会支持在内的完整治疗计划的一部分。

IMPORTANT SAFETY INFORMATION

重要安全信息

WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY

警告：静脉注射有严重伤害或死亡的风险；BRIXADI风险评估和缓解策略

Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously.

如果静脉注射，可能导致严重伤害或死亡。BRIXADI与体液接触后形成液晶凝胶，如果静脉注射，可能会导致阻塞，局部组织损伤和血栓栓塞事件，包括危及生命的肺栓塞。

Because of the risk of serious harm or death that could result from intravenous self-administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements.   .

由于静脉内自我管理可能导致严重伤害或死亡的风险，BRIXADI只能通过一个名为BRIXADI REMS的受限程序获得。订购和分发BRIXADI的医疗机构和药店必须通过本计划的认证，并符合REMS要求。。

BRIXADI (buprenorphine) extended-release injection (weekly, 50 mg/mL buprenorphine) and BRIXADI (monthly, 356 mg/mL buprenorphine) are different formulations. Doses of BRIXADI (weekly) cannot be combined to yield an equivalent monthly dose.

BRIXADI（丁丙诺啡）缓释注射液（每周50毫克/毫升丁丙诺啡）和BRIXADI（每月356毫克/毫升丁丙诺啡）是不同的配方。BRIXADI（每周）的剂量不能合并产生等效的每月剂量。

BRIXADI is contraindicated in patients with hypersensitivity (e.g. anaphylactic shock) to buprenorphine or any other ingredients in the solution for injection.

BRIXADI禁用于对丁丙诺啡或注射溶液中任何其他成分过敏（例如过敏性休克）的患者。

WARNINGS AND PRECAUTIONSAddiction, Abuse, and Misuse: BRIXADI contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Buprenorphine is sought by people with opioid use disorder and is subject to criminal diversion. Monitor all patients for progression of opioid dependence and addictive behaviors. .

警告和预防措施预防，滥用和滥用：BRIXADI含有丁丙诺啡，这是一种附表III管制物质，可以以类似于其他阿片类药物的方式滥用。。监测所有患者阿片类药物依赖和成瘾行为的进展。。

Respiratory and CNS Depression: Buprenorphine has been associated with life-threatening respiratory depression and death. Use BRIXADI with caution in patients with compromised respiratory function. Due to its extended-release characteristics, if BRIXADI is discontinued as a result of compromised respiratory function, monitor patients for ongoing buprenorphine effects for approximately 1 month for BRIXADI (weekly) and for approximately 4 months for BRIXADI (monthly).

呼吸和中枢神经系统抑制：丁丙诺啡与危及生命的呼吸抑制和死亡有关。呼吸功能受损的患者应谨慎使用BRIXADI。由于其缓释特性，如果BRIXADI因呼吸功能受损而停用，则监测患者持续丁丙诺啡作用约1个月（每周）和约4个月（每月）。

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose..

。。

Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose: Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver. Because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose, strongly consider prescribing naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with BRIXADI.

患者获得纳洛酮用于阿片类药物过量的紧急治疗：与患者和护理人员讨论纳洛酮用于阿片类药物过量紧急治疗的可用性。由于接受阿片类药物使用障碍治疗的患者有复发的可能性，使他们面临阿片类药物过量的风险，因此在开始和恢复使用BRIXADI治疗时，强烈考虑使用纳洛酮紧急治疗阿片类药物过量。

If naloxone is prescribed, educate patients and caregivers on how to treat with naloxone, and emphasize the importance of calling 911 or getting emergency medical help, even if naloxone is administered. .

如果开了纳洛酮，教育患者和护理人员如何使用纳洛酮，并强调拨打911或获得紧急医疗帮助的重要性，即使服用了纳洛酮。。

Concomitant Use of Benzodiazepines or other CNS Depressants: Concomitant use of buprenorphine and benzodiazepines or other CNS depressants increase the risk of adverse reactions including respiratory depression, overdose and death. Ensure that other healthcare providers prescribing benzodiazepines or other CNS depressants are aware of the patient's buprenorphine treatment and coordinate care to minimize the risk associated with concomitant use.

同时使用苯二氮卓类药物或其他中枢神经系统抑制剂：同时使用丁丙诺啡和苯二氮卓类药物或其他中枢神经系统抑制剂会增加不良反应的风险，包括呼吸抑制，过量用药和死亡。确保处方苯二氮卓类药物或其他中枢神经系统抑制剂的其他医疗保健提供者了解患者的丁丙诺啡治疗，并协调护理，以最大程度地降低伴随使用的风险。

Inform patients and caregivers that potentially fatal additive effects may occur if BRIXADI is used with benzodiazepines or other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a healthcare provider..

告知患者和护理人员，如果BRIXADI与苯二氮卓类药物或其他中枢神经系统抑制剂（包括酒精）一起使用，可能会产生致命的累加效应，除非在医疗保健提供者的监督下，否则不要同时使用。。

Neonatal Opioid Withdrawal Syndrome, Pregnancy, and Lactation: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. NOWS may be life-threatening if not recognized and treated in the neonate. Healthcare providers should observe newborns for signs of NOWS and manage accordingly.

新生儿阿片类药物戒断综合征，妊娠和哺乳期：新生儿阿片类药物戒断综合征（NOWS）是怀孕期间长期使用阿片类药物的预期和可治疗的结果。如果在新生儿中不被识别和治疗，NOWS可能会危及生命。医疗保健提供者应观察新生儿是否有NOWS的迹象，并进行相应的管理。

Advise pregnant women receiving opioid addiction treatment with BRIXADI of the risk of neonatal opioid withdrawal syndrome. Warn patients that buprenorphine passes into breast milk. Advise the nursing mother taking buprenorphine to monitor the infant for increased drowsiness and breathing difficulties. .

建议接受BRIXADI阿片类药物成瘾治疗的孕妇注意新生儿阿片类药物戒断综合征的风险。警告患者丁丙诺啡会进入母乳。建议服用丁丙诺啡的哺乳母亲监测婴儿的嗜睡和呼吸困难。。

Adrenal Insufficiency: If adrenal insufficiency is diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.

肾上腺皮质功能不全：如果诊断出肾上腺皮质功能不全，则进行生理性皮质类固醇替代治疗，并使患者停止服用阿片类药物。

Risk of Opioid Withdrawal with Abrupt Discontinuation: Patients who elect to discontinue BRIXADI treatment should be monitored for withdrawal signs and symptoms with consideration given to the product's extended-release characteristics.

阿片类药物突然停药的风险：选择停止BRIXADI治疗的患者应监测停药迹象和症状，并考虑产品的缓释特性。

Risk of Hepatitis, Hepatic Events, and Use in Patients with Impaired Hepatic Function: Liver function tests should be performed on all patients prior to initiation, during treatment, and if a hepatic event is suspected. Because buprenorphine levels cannot be rapidly decreased, patients with pre–existing moderate to severe hepatic impairment are not candidates for treatment with BRIXADI.

肝功能受损患者发生肝炎，肝事件和使用的风险：在开始之前，治疗期间以及怀疑有肝事件时，应对所有患者进行肝功能检查。由于丁丙诺啡水平不能迅速降低，因此先前存在中度至重度肝功能损害的患者不适合使用BRIXADI治疗。

Patients who develop moderate to severe hepatic impairment while being treated with BRIXADI should be monitored for signs and symptoms of toxicity or overdose of buprenorphine and may require a dose adjustment..

在接受BRIXADI治疗时出现中度至重度肝功能损害的患者应监测毒性或丁丙诺啡过量的体征和症状，并可能需要调整剂量。。

Hypersensitivity Reactions: Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients receiving buprenorphine-containing products. The most common signs and symptoms include rashes, hives, and pruritus. The BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in latex-sensitive individuals. .

超敏反应：据报道，接受含丁丙诺啡产品的患者出现支气管痉挛，血管神经性水肿和过敏性休克。最常见的体征和症状包括皮疹、荨麻疹和瘙痒症。BRIXADI针帽由天然胶乳合成而成，可能会导致乳胶敏感个体发生过敏反应。。

Precipitation of Opioid Withdrawal in Patients Dependent on Full Opioid Agonists: BRIXADI injection may precipitate opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists such as heroin, morphine, or methadone before the effects of the full opioid agonist have subsided.

依赖完全阿片类激动剂的患者阿片类药物戒断的沉淀：在完全阿片类激动剂的作用消退之前，BRIXADI注射可能会在身体上依赖完全阿片类激动剂（如海洛因，吗啡或美沙酮）的个体中沉淀阿片类药物戒断的体征和症状。

In patients who are new entrants to treatment, to avoid precipitating an opioid withdrawal syndrome, administer a 4 mg test dose of transmucosal buprenorphine when objective signs of mild to moderate withdrawal appear and monitor for precipitated withdrawal before injecting BRIXADI. .

对于新进入治疗的患者，为了避免诱发阿片类药物戒断综合征，当出现轻度至中度戒断的客观迹象时，给予4 mg测试剂量的经粘膜丁丙诺啡，并在注射BRIXADI之前监测是否有突然戒断。。

Risks Associated with Treatment of Emergent Acute Pain:  While on BRIXADI, situations may arise where patients need acute pain management, or may require anesthesia. Treat patients receiving BRIXADI with non-opioid analgesic whenever possible. Patients requiring opioid therapy for analgesia may be treated with a high-affinity full opioid analgesic under the supervision of a healthcare provider, with particular attention to respiratory function.

与紧急急性疼痛治疗相关的风险：在使用BRIXADI时，可能会出现患者需要急性疼痛管理或可能需要麻醉的情况。尽可能用非阿片类镇痛药治疗接受BRIXADI治疗的患者。需要阿片类药物治疗镇痛的患者可以在医疗保健提供者的监督下用高亲和力的全阿片类镇痛药治疗，特别注意呼吸功能。

Higher doses may be required for analgesic effect. Therefore, a higher potential for toxicity exists with opioid administration. Advise patients of the importance of instructing their family members, in the event of emergency, to inform the treating healthcare provider or emergency room staff that the patient is being treated with BRIXADI. .

镇痛效果可能需要更高剂量。因此，阿片类药物给药存在更高的毒性潜力。告知患者在紧急情况下指导其家人的重要性，告知治疗保健提供者或急诊室工作人员患者正在接受BRIXADI治疗。。

Use in Opioid Naïve Patients: There have been reported deaths of opioid naïve individuals who received a 2 mg dose of buprenorphine as a sublingual tablet. BRIXADI is not appropriate for use in opioid naïve patients.

在未服用阿片类药物的患者中使用：据报道，未服用阿片类药物的个体死亡，他们接受了2 mg剂量的丁丙诺啡作为舌下片剂。BRIXADI不适合用于未服用阿片类药物的患者。

Patients at Risk for Arrhythmia: Thorough QT studies with buprenorphine products have demonstrated QT prolongation ≤ 15 msec. This QTc prolongation effect does not appear to be mediated by hERG channels. Based on these two findings, buprenorphine is unlikely to be pro-arrhythmic when used alone in patients without risk factors.

心律失常风险患者：丁丙诺啡产品的全面QT研究表明QT延长≤15毫秒。这种QTc延长效应似乎不是由hERG通道介导的。基于这两个发现，丁丙诺啡在没有危险因素的患者中单独使用不太可能导致心律失常。

The risk of combining buprenorphine with other QT-prolonging agents is not known. .

丁丙诺啡与其他QT延长剂联合使用的风险尚不清楚。。

Impairment of Ability to Drive and Operate Machinery: BRIXADI may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. Caution patients about driving or operating hazardous machinery until they are reasonably certain that BRIXADI does not adversely affect their ability to engage in such activities..

驾驶和操作机器的能力受损：BRIXADI可能会损害执行潜在危险任务（如驾驶汽车或操作机器）所需的精神或身体能力。提醒患者驾驶或操作危险机械，直到他们合理地确定BRIXADI不会对他们从事此类活动的能力产生不利影响。。

Orthostatic Hypotension: Buprenorphine may produce orthostatic hypotension in ambulatory patients.

体位性低血压：丁丙诺啡可能在门诊患者中产生体位性低血压。

Elevation of Cerebrospinal Fluid Pressure: Buprenorphine may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased.

脑脊液压力升高：丁丙诺啡可能会升高脑脊液压力，对于头部受伤，颅内病变和其他脑脊液压力可能升高的情况，应谨慎使用。

Elevation of Intracholedochal Pressure: Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract.

胆总管内压升高：丁丙诺啡已被证明与其他阿片类药物一样可增加胆总管内压，因此应谨慎使用胆道功能障碍患者。

Effects in Acute Abdominal Conditions: Buprenorphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

对急腹症的影响：丁丙诺啡可能会模糊急腹症患者的诊断或临床过程。

Unintentional Pediatric Exposure: Buprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentally exposed to it.

儿童意外接触丁丙诺啡：丁丙诺啡可导致意外接触丁丙诺啡的儿童出现严重的，可能致命的呼吸抑制。

ADVERSE REACTIONS Adverse reactions commonly associated with BRIXADI administration (in ≥5% of patients) were injection site pain, headache, constipation, nausea, injection site erythema, injection site pruritus, insomnia, and urinary tract infection.

不良反应通常与BRIXADI给药相关的不良反应（在≥5%的患者中）是注射部位疼痛，头痛，便秘，恶心，注射部位红斑，注射部位瘙痒，失眠和尿路感染。

To report SUSPECTED ADVERSE REACTIONS, contact Braeburn at 1-833-274-9234 or FDA at 1-800-FDA1088 or www.fda.gov/medwatch.

要报告疑似不良反应，请联系Braeburn（电话：1-833-274-9234）或FDA（电话：1-800-FDA1088）或www.FDA.gov/medwatch。

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

。

About BraeburnBraeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. At Braeburn, we challenge the status quo and champion transformation of the management of opioid use disorder (OUD) by partnering with the community to create a world where every person with OUD gets the best possible care and opportunity to reach their full potential.

关于Braeburn Braeburn致力于为患有阿片类药物使用障碍严重后果的人提供解决方案。在布雷伯恩，我们通过与社区合作，创造一个每个患有阿片类药物使用障碍（OUD）的人都能获得尽可能最好的护理和机会以充分发挥其潜力的世界，从而挑战现状并支持阿片类药物使用障碍（OUD）管理的转变。

Visit https://braeburnrx.com to learn more. Connect with Braeburn on LinkedIn at https://linkedin.com/company/Braeburn..

访问https://braeburnrx.com了解更多。在LinkedIn上连接Braeburnhttps://linkedin.com/company/Braeburn..

Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(6):764–773. doi:10.1001/jamainternmed.2018.1052.

Lofwall MR，Walsh SL，Nunes EV等。每周和每月皮下丁丙诺啡贮库制剂与每日舌下丁丙诺啡联合纳洛酮治疗阿片类药物使用障碍：一项随机临床试验。JAMA实习生医学2018；178（6）：764-773。doi:10.1001/jamainternmed.2018.1052。

For additional information, please contact: Sabrina Romano: SRomano@braeburnrx.com

有关更多信息，请联系：Sabrina Romano：SRomano@braeburnrx.com

SOURCE Braeburn

源Braeburn